01:44 , Feb 25, 2017 |  BioCentury  |  Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
00:55 , Feb 24, 2017 |  BC Innovations  |  Product R&D

Two firsts for Zika

While companies are exploring a variety of traditional and emerging vaccine strategies to prevent Zika infection, two studies published this month suggest the newest modality - mRNA-based vaccines - could be competitive. The studies, from...
20:27 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

CV9104: Ph IIb data

Top-line data from the Phase IIb portion of a double-blind, European Phase I/IIb trial in 197 chemotherapy-naïve, asymptomatic or minimally symptomatic patients with metastatic CRPC showed that intradermal CV9104 missed the primary endpoint of improving...
00:39 , Jan 12, 2017 |  BC Extra  |  Clinical News

CureVac's prostate cancer vaccine fails in Phase IIb trial

CureVac AG (Tuebingen, Germany) said its lead vaccine candidate CV9104 failed to improve overall survival in a Phase IIb study to treat castration-resistant prostate cancer (CRPC), missing its primary endpoint. The company presented the results...
18:21 , Nov 18, 2016 |  BioCentury  |  Finance

Diversifying CureVac

CureVac AG ’s most recent financing is another step toward diversifying the RNA company’s shareholder base to make it more attractive to U.S. investors. On Nov. 8, CureVac raised $29.5 million in the second tranche...
23:50 , Nov 8, 2016 |  BC Extra  |  Financial News

CureVac raises $29.5M

CureVac AG (Tuebingen, Germany) raised $29.5 million in a private round led by two new investors -- Baden-Wuerttembergische Versorgungsanstalt fuer Aerzte, Zahnaerzte und Tieraerzte; and Landeskreditbank Baden-Wuerttemberg. CureVac said it has now raised about $360...
02:15 , Nov 4, 2015 |  BC Extra  |  Financial News

CureVac raises $110M in private placement

CureVac AG (Tuebingen, Germany) raised $110 million in a private placement led by new investor Baillie Gifford. New investors Chartwave Ltd., Coppel Family, Elma Investments Ltd. and Sigma Group also participated, as did existing investors...
07:00 , Sep 29, 2014 |  BioCentury  |  Finance

CureVac bet paying off

Although the Hopp family's biotech investments have posted mixed results in recent years, the €80 million marker Hopp put down in 2012 on CureVac GmbH seems to be paying off. The cancer vaccine and infectious...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

CureVac infectious news

The European Commission awarded CureVac a €2 million ($2.8 million) innovation inducement prize to develop its RNActive vaccine technology. In April 2012, the EC opened the call for proposals for solutions to keeping vaccines stable...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

CV9104: Phase I/IIb completed enrollment

CureVac completed enrollment of >195 chemotherapy-naïve patients with asymptomatic or minimally symptomatic CRPC in a double-blind, placebo-controlled, European Phase I/IIb trial evaluating intradermal CV9104. CureVac GmbH , Tuebingen, Germany   Product: CV9104   Business: Cancer...